Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.

by Raphael Gottardo, Robert T Bailer, Bette T Korber, S Gnanakaran, Joshua Phillips, Xiaoying Shen, Georgia D Tomaras, Ellen Turk, Gregory Imholte, Larry Eckler, Holger Wenschuh, Johannes Zerweck, Kelli Greene, Hongmei Gao, Phillip W Berman, Donald Francis, Faruk Sinangil, Carter Lee, Sorachai Nitayaphan, Supachai Rerks-Ngarm, Jaranit Kaewkungwal, Punnee Pitisuttithum, James Tartaglia, Merlin L Robb, Nelson L Michael, Jerome H Kim, Susan Zolla-Pazner, Barton F Haynes, John R Mascola, Steve Self, Peter Gilbert, David C Montefiori
Published 2013-01-01